Clinical trial · Observational
IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer
A Prospective Study Assessing the Correlation Between Disease Prognosis and the Level of IL-6 and IL-8 Level in Blood and Pleural Effusion Before and After Chemotherapy in Patients With Metastatic Breast Cancer
NCT01543126CI-TRIAL-00011485terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): it's too slow to enroll suitable patients into this study
Summary
Brief summary (as posted)
Change of IL-6 and IL-8 level in blood and pleural effusion before and after chemotherapy correlate with the prognosis of the disease
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- pleural effusion
- description
- patients with pleural effusion
Primary outcomes (1)
- measure
- level of IL-6 and IL-8
- timeFrame
- 2 days
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Female between 18 and 70 years old; * Patients with histologic proved metastatic breast cancer; * Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or ultrasound; * There are no other diseases which cause the elevation of IL-6 or IL-8, such as cirrhosis of liver, anaphylactoid purpura, acute pancreatitis; * With at least one measurable disease according to RECIST criteria, * Normal laboratory results:ANC≥2.0×109/L,Hb≥80g/L,plt≥100×109/L,TB\<UNL (\<1.5 x UNL in patients with liver mets),ALT/AST\< 1.5 x UNL (\<2.5x UNL in patients with liver mets),AKP\<5 x UNL(except bone mets),Cr\<UNL; * Normal functions with heart, liver,renal and bone marrow; * Got ICF before enrollment; * Life expectancy more than 12 weeks. Exclusion Criteria: * Pregnant or breast-feeding women or positive serum pregnancy test; * Uncontrolled brain metastases; * No recovery from previous radiation or accepted radiation within 4 weeks before enrollment; * Participation in any investigational drug study within 4 weeks preceding treatment start; * Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin; * Serious uncontrolled intercurrent infections; * Poor compliance.
References
Publications (0)
Data not yet available
No reference posted for this study.